These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35870702)

  • 1. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB.
    Yuen MF; Locarnini S; Lim TH; Strasser SI; Sievert W; Cheng W; Thompson AJ; Given BD; Schluep T; Hamilton J; Biermer M; Kalmeijer R; Beumont M; Lenz O; De Ridder F; Cloherty G; Ka-Ho Wong D; Schwabe C; Jackson K; Lai CL; Gish RG; Gane E
    J Hepatol; 2022 Nov; 77(5):1287-1298. PubMed ID: 35870702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
    Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M;
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.
    Janssen HLA; Hou J; Asselah T; Chan HLY; Zoulim F; Tanaka Y; Janczewska E; Nahass RG; Bourgeois S; Buti M; Lampertico P; Lenz O; Verbinnen T; Vandenbossche J; Talloen W; Kalmeijer R; Beumont M; Biermer M; Shukla U
    Gut; 2023 Jul; 72(7):1385-1398. PubMed ID: 36697207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B: REEF-2.
    Agarwal K; Buti M; van Bömmel F; Lampertico P; Janczewska E; Bourliere M; Vanwolleghem T; Lenz O; Verbinnen T; Kakuda TN; Mayer C; Jezorwski J; Muenz D; Beumont M; Kalmeijer R; Biermer M; Lonjon-Domanec I
    J Hepatol; 2024 Apr; ():. PubMed ID: 38583491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B.
    Gane E; Yuen MF; Kakuda TN; Ogawa T; Takahashi Y; Goeyvaerts N; Lonjon-Domanec I; Vaughan T; Schluep T; Hamilton J; Njumbe Ediage E; Hillewaert V; Snoeys J; Lenz O; Talloen W; Biermer M
    Antivir Ther; 2022 Jun; 27(3):13596535221093856. PubMed ID: 35695169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection.
    Zoulim F; Lenz O; Vandenbossche JJ; Talloen W; Verbinnen T; Moscalu I; Streinu-Cercel A; Bourgeois S; Buti M; Crespo J; Manuel Pascasio J; Sarrazin C; Vanwolleghem T; Shukla U; Fry J; Yogaratnam JZ
    Gastroenterology; 2020 Aug; 159(2):521-533.e9. PubMed ID: 32343960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy.
    Hsu WF; Chen CF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen CH; Wang HW; Huang GT; Peng CY
    Liver Int; 2018 Apr; 38(4):627-635. PubMed ID: 28857411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression.
    Gane EJ; Dunbar PR; Brooks AE; Zhang F; Chen D; Wallin JJ; van Buuren N; Arora P; Fletcher SP; Tan SK; Yang JC; Gaggar A; Kottilil S; Tang L
    J Hepatol; 2023 Mar; 78(3):513-523. PubMed ID: 38133554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.
    Yuen MF; Heo J; Kumada H; Suzuki F; Suzuki Y; Xie Q; Jia J; Karino Y; Hou J; Chayama K; Imamura M; Lao-Tan JY; Lim SG; Tanaka Y; Xie W; Yoon JH; Duan Z; Kurosaki M; Park SJ; Labio ME; Kumar R; Kweon YO; Yim HJ; Tao Y; Cremer J; Elston R; Davies M; Baptiste-Brown S; Han K; Campbell FM; Paff M; Theodore D
    J Hepatol; 2022 Oct; 77(4):967-977. PubMed ID: 35714812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 in the JADE phase 2a study.
    Verbinnen T; Talloen W; Janssen HLA; Zoulim F; Shukla U; Vandenbossche JJ; Biermer M; De Meyer S; Lenz O
    Antiviral Res; 2023 Aug; 216():105660. PubMed ID: 37385475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B.
    Striki A; Manolakopoulos S; Deutsch M; Kourikou A; Kontos G; Kranidioti H; Hadziyannis E; Papatheodoridis G
    Liver Int; 2017 Nov; 37(11):1642-1650. PubMed ID: 28345181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
    García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
    J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA interference as a novel treatment strategy for chronic hepatitis B infection.
    Hui RW; Mak LY; Seto WK; Yuen MF
    Clin Mol Hepatol; 2022 Jul; 28(3):408-424. PubMed ID: 35172540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients.
    Hou J; Gane E; Balabanska R; Zhang W; Zhang J; Lim TH; Xie Q; Yeh CT; Yang SS; Liang X; Komolmit P; Leerapun A; Xue Z; Chen E; Zhang Y; Xie Q; Chang TT; Hu TH; Lim SG; Chuang WL; Leggett B; Bo Q; Zhou X; Triyatni M; Zhang W; Yuen MF
    Clin Mol Hepatol; 2024 Apr; 30(2):191-205. PubMed ID: 38190830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A retrospective follow-up study of prolonged nucleos(t)ide analogue and interferon combination therapy in HBeAg-positive chronic hepatitis B patients].
    Yu SL; Guo CY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Apr; 21(4):267-70. PubMed ID: 24021787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.